Abstract | PURPOSE: METHODS: RESULTS: : No significant difference in the cytokine levels was noted between the control group and the naïve CNV group (all P > 0.05). Vascular endothelial growth factor in both naive (66.8 +/- 35.1 pg/mL) and recurrent CNV groups (55.7 +/- 63.0 pg/mL) was significantly higher compared with regressed CNV group (9.8 +/- 12.8 pg/mL, P = 0.025 and P = 0.004, respectively) but was not statistically different from the control group (81.8 +/- 43.7 pg/mL, P = 0.310 and P = 0.212, respectively). The aqueous humor level of tumor necrosis factor-alpha and interleukin (IL)-2 was significantly lower in recurrent CNV group (P = 0.036 and P = 0.019) compared with the control group. In the active CNV patients (recurrent and naïve CNV groups), the aqueous humor levels of IL-6 and IL-8 significantly correlated with the size of CNV (rho = 0.692, P = 0.001 and rho = 0.745, P < 0.001, respectively). CONCLUSION:
|
Authors | Mi In Roh, Hong Suk Kim, Ji Hun Song, Jong Baek Lim, Hyoung Jun Koh, Oh Woong Kwon |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 29
Issue 4
Pg. 523-9
(Apr 2009)
ISSN: 1539-2864 [Electronic] United States |
PMID | 19262441
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Cytokines
- Interleukin-2
- Interleukin-6
- Interleukin-8
- Tumor Necrosis Factor-alpha
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Aqueous Humor
(metabolism)
- Bevacizumab
- Choroidal Neovascularization
(etiology, metabolism, physiopathology, prevention & control)
- Cytokines
(metabolism)
- Female
- Humans
- Interleukin-2
(metabolism)
- Interleukin-6
(metabolism)
- Interleukin-8
(metabolism)
- Macular Degeneration
(complications, drug therapy, metabolism)
- Male
- Middle Aged
- Osmolar Concentration
- Recurrence
- Tumor Necrosis Factor-alpha
(metabolism)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|